GSK plc announced on September 11, 2024, that its phase II trial of a therapeutic HSV vaccine did not meet its primary efficacy objectives, thus it will not proceed to phase III; however, ongoing safety monitoring will continue.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.